Furthermore, administration of the pan-sPLA2 inhibitor varespladib into humanized mice markedly prevents EBV-induced lymphoma development likely by inhibiting endogenous sPLA2-X or other varespladib-sensitive sPLA2s, whereas that of sPLA2-X-modified EVs facilitates this event (49). This evidence concerns the gene PLA2G10 and lymphoma.